This is a summary of the European public assessment report (EPAR) for Prometax. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prometax.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Therapeutic Area (MeSH)
N/AATC Code
N06DA03
ATC Item
rivastigmine
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| rivastigmine | N/A | 利斯的明 |
EMA Name
Prometax
Medicine Name
Prometax
Aliases
N/ANo risk management plan link.
